Rakuten and SBI have returned to chip into the precision immunotherapy developer’s series D round, which was led by General Catalyst.
US-headquartered cancer therapy developer Rakuten Medical closed a $166m series D round yesterday featuring e-commerce group Rakuten and financial services firm SBI Holdings.
Venture capital firm General Catalyst led the round, which consisted of $75m in fresh capital and $91m of converted stocks from convertible notes with accrued interest. Unnamed returning investors filled out the participants in the round.
Founded in 2013 and formerly known as Aspyrian Therapeutics, Rakuten Medical is developing precision cellular therapies leveraging its Illuminox platform that…
